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Abstract
Many cancer predisposition syndromes are rare or have incomplete penetrance, and traditional epidemiological tools are
not well suited for their detection. Here we have used an approach that employs the entire population based data in the
Finnish Cancer Registry (FCR) for analyzing familial aggregation of all types of cancer, in order to find evidence for previously
unrecognized cancer susceptibility conditions. We performed a systematic clustering of 878,593 patients in FCR based on
family name at birth, municipality of birth, and tumor type, diagnosed between years 1952 and 2011. We also estimated the
familial occurrence of the tumor types using cluster score that reflects the proportion of patients belonging to the most
significant clusters compared to all patients in Finland. The clustering effort identified 25,910 birth name-municipality based
clusters representing 183 different tumor types characterized by topography and morphology. We produced information
about familial occurrence of hundreds of tumor types, and many of the tumor types with high cluster score represented
known cancer syndromes. Unexpectedly, Kaposi sarcoma (KS) also produced a very high score (cluster score 1.91, p-value
,0.0001). We verified from population records that many of the KS patients forming the clusters were indeed close
relatives, and identified one family with five affected individuals in two generations and several families with two first
degree relatives. Our approach is unique in enabling systematic examination of a national epidemiological database to
derive evidence of aberrant familial aggregation of all tumor types, both common and rare. It allowed effortless
identification of families displaying features of both known as well as potentially novel cancer predisposition conditions,
including striking familial aggregation of KS. Further work with high-throughput methods should elucidate the molecular
basis of the potentially novel predisposition conditions found in this study.
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Introduction
Identification of inherited genetic factors that contribute to the
development of cancer has been a subject of extensive research
since the discovery of the first tumor susceptibility genes. Various
approaches have been used to estimate the proportion of the
inherited versus environmental factors in the etiology of different
cancers. Twin studies have elucidated a large heritable fraction
(26%–42%) for many common cancers, such as those of stomach,
colon/rectum, breast, prostate, and lung [1]. Systematic registry-
based analyses have shown a significantly increased risk for
example for brain tumors, various lymphoma subtypes, and
gastrointestinal neuroendocrine tumors in family members of
affected individuals [2–5].
The earliest examples of cancer predisposing genes were
identified in large cancer syndrome families. These families are
rare and the contribution of these genes to the cancer burden as
a whole is relatively small. For example, high-penetrance
mutations in genes such as MLH1, MSH2, APC, and MYH
account for only about 5% of all colorectal cancer cases [6].
However, identification of cancer predisposing genes has contrib-
uted significantly to our understanding of cancer biology, since
they are often central also in the development of sporadic tumors.
The genetic background of the Finnish population (currently 5.4
million) is relatively well-studied and, even though considered
relatively homogenous, has been shown to harbor substantial
substructuring [7]. Ten distinct subpopulations of Finns have been
characterized with high-density SNP genotyping suggesting
multiple bottlenecks in the history of the Finnish population.
After internal migration in the 1500s, population size of the wide
inland areas of Finland grew in isolation because of long distances,
and small villages formed genetically distinct subpopulations.
Some degree of genetic admixture and migration due to
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urbanization started taking place after World War II. Single-origin
mutations which have spread without negative effect on biological
fitness have accounted for highly prevalent diseases in some of
these isolated populations. This founder effect has enabled
successful identification of genetic susceptibility to diseases in
Finland (reviewed in [8]). As an example, the discovery of familial
pituitary adenoma clusters in Northern Finland led to the
identification of aryl hydrocarbon receptor interacting protein (AIP) defects
in patients with pituitary adenoma predisposition [9]. Mutations in
AIP originally identified in Finland have subsequently been found
from similar patients worldwide [10].
The Finnish Cancer Registry (FCR) is a nation-wide database
covering currently more than one million patients, and practically
all incident cancers and cancer deaths in Finland since 1953 [11].
Physicians, hospitals, and pathology and hematology laboratories
send cancer notifications to FCR. This reporting was made
obligatory by law in 1961. Thus, FCR has also a link to sample
information, such as archival tissue blocks, for all the patients that
have been examined in pathology laboratories. Information about
family history and family relationships is not recorded in the
cancer notifications, but identification of patients’ relatives is
possible through the National Population Registry (NPR) and the
Parish Registries (PRs). PRs have kept records of citizens since
1580 until NPR was established. The personal identity code (PIC)
system was implemented in Finland in the 1960s, and PIC is used
as the identification key also in FCR for all patients except for
those who died before 1967. Both FCR and NPR have an
excellent coverage and high quality data [11,12].
Conventional epidemiological tools are poorly suited to search
for evidence of cancer predisposition, in particular if the conditions
in question are uncommon. Here we describe an effective method
that utilizes the extensive patient data in FCR, and information
about family name at birth and municipality of birth in NPR, to
systematically identify familial aggregation of all different tumor
types on a nation-wide scale. The method enables identification of
families suitable for sample collection and further research of the
underlying genetic predisposition. Similar approach in a smaller
scale has earlier been exploited in a search for prostate cancer
families in Finland [13]. In this study, we apply our method to
cluster all available patients in FCR. We calculate statistical
significance for each cluster, and produce information about
familial occurrence of hundreds of tumor types. We describe in
detail a strong familial aggregation and uneven geographical
distribution of Kaposi sarcoma (KS) in Finland. Furthermore, we
report several families with two first degree relatives and a striking
family of five cases with KS.
Materials and Methods
Ethical Considerations
The research registry and data processing procedures were
evaluated and approved by the Ministry of Social Affairs and
Health in Finland.
Patient Data in the Finnish Cancer Registry
We considered 1,175,040 neoplasms registered in 1953–2011 in
FCR. This included 212,685 cases of certain commonly registered
precancerous lesions such as basal cell carcinoma of skin and
polycythemia vera (registered since 1969). Currently, the disease
classification in FCR is based on the ICD-oncology, 3rd edition.
Systematic Clustering
Prior to clustering, the tumor types were classified further to
topography and morphology groups (Tables S1 and S2). Tumor
types with at least two patients in FCR were included, resulting in
846 combinations of topography and morphology (Table S3). To
obtain information on patients’ family names at birth and
municipalities of birth, we linked the 878,593 patients with PIC
to NPR.
For each tumor type, systematic clustering was performed based
on municipality of birth and family name at birth (MN-clusters).
The observed number of patients (O) with each tumor type in
FCR was calculated in a stratum defined by municipality (M),
family name (N), sex, and year of birth. The proportion of persons
in each M, N, sex, and year of birth category in the entire
population of same gender and year of birth was calculated from
the same version of NPR database that was linked with FCR
patients. When that proportion was multiplied with the total sex
and birth-year specific number of cancer cases of the cancer type
in question in the NPR-linked subset of FCR, the expected
number of cases (E) in each stratum was obtained. The stratum-
specific observed and expected numbers were added up over the
gender and birth year categories. O/E ratios were calculated for
each MN category, and their 95% confidence intervals were
defined assuming a Poisson distribution of observed numbers.
Estimation of Familial Occurrence with Cluster Score
To estimate the familial occurrence of various tumor types,
cluster score was calculated. For each tumor type i, we selected
clusters with the lower limit of confidence interval (CI-low) greater
than or equal to a, and calculated the number of patients (Xia) in
these clusters.
We define the cluster score of tumor type i to be Xia divided by
the total number of patients with the same tumor type (Yi) per
100,000 persons in Finland. For example, cluster score with a=10
for Kaposi sarcoma was calculated as following (X=19 and
Y=537 from Table 1):
19=537  5,400,000=100,000~1:91:
To estimate whether Xia/Yi was different than expected ratio
Yi*Xa/Y (where Xa/Y is the respective ratio over all tumor types
in Finland; 0.0029 for a=10), two-sided Poisson test was
calculated with 95% confidence level. The p-values were adjusted
for multiple test comparisons with false discovery rate method
[14].
Confirmation of Kinship in the Clustered Kaposi Sarcoma
Cases
Relatedness of patients in KS clusters was confirmed using
information from NPR and PRs. NPR includes a link to parents
for persons born since 1950s and who had not died before the PIC
system was implemented in the 1960s. For the rest of the patients,
we utilized PRs to identify first degree relatives and their children.
PRs were also utilized for more thorough genealogy research. The
relatives of the clustered KS cases were traced back at least three
generations. To identify additional affected cases in the families,
the cancer histories were checked from FCR for individuals
identified through genealogy.
Geographical Illustration of Kaposi Sarcoma in Finland
The O/E ratios for Kaposi sarcoma cases in each municipality
of birth were calculated as described previously for MN-clusters,
and illustrated using the small-area mapping method developed in
FCR [15]. The twenty-one largest cities in Finland, including
Vyborg (currently part of Russia), are shown as circles with
Registry-Based Analysis of Cancer Clustering
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a diameter relative to E, and with the color shading indicating the
O/E ratio in that city. The remaining map area illustrates the
floating averages of the O/E ratios of the neighboring municipal-
ities, excluding the largest cities. The map was based on borders of
Finland before year 1940 because a large proportion of the KS
patients were born before that.
Determination of HHV8 Seroprevalence in Finland
To estimate Human herpesvirus 8 (HHV8) infection rate in
Finland, serological testing was performed in age and sex matched
serum samples of 200 Eastern and 200 Western Finns obtained
from the National Public Health Institute’s Health 2000 cohort.
The serological analyses were done at HUSLAB (Helsinki,
Finland) with direct HHV8 IgG antibody Enzyme Linked
ImmunoSorbent Assay.
Results
We clustered 878,593 cases in FCR to assess the familial
aggregation of various tumor types defined by topography and
morphology. The clustering was performed based on tumor type,
municipality of birth, and family name at birth (MN-clusters). As
a result, we identified 25,910 MN-clusters representing 183
combinations of topography and morphology (see Table S3 for
distribution of cases). All the clusters fulfilled the criterion that the
number of cases in the cluster was higher than the expected
number based on the distribution of family names and birth
municipalities in Finland, with CI-low$1.
We also sought to estimate the tumor types that showed
strongest evidence for familial occurrence, and for that we
calculated cluster score for tumor types that produced significant
MN-clusters. The clusters with the strongest confidence, CI-
low$10, were considered, encompassing 4.7% of all MN-clusters
and representing 169 tumor types (Table S3). This corresponds to
0.3% of the patients in FCR.
Tumor types and respective cluster scores with FDR adjusted p-
values,0.0001 are displayed in Table 1. Cluster scores and p-
values for all tumor types are listed in Table S3. Most of the top
scoring tumor types indicated rare cancer predisposition syn-
dromes. The most frequently clustered tumor type was hemangio-
blastoma, a common finding in patients with the Von Hippel-
Lindau syndrome (VHL [MIM #193300]) (cluster score 4.98).
The second most frequently clustered tumor type was medullary
thyroid carcinoma indicative of patients with Multiple Endocrine
Neoplasia type 2 (MEN2A [#171400] and MEN2B [#162300])
(cluster score 3.55). Among the most common tumor types
showing strong evidence for familial occurrence were papillary
thyroid adenocarcinoma (cluster score 0.56), chronic lymphatic
leukemia (cluster score 0.48), and squamous cell carcinoma of the
lip (cluster score 0.35), all with over 7000 registered patients in
FCR (Table 1).
Kaposi Sarcoma
Familial occurrence of KS, the third most frequently clustered
tumor type (cluster score 1.91), was further studied through
genealogy as an example of the procedure to be followed with
promising clusters in the systematic search. Out of the 23 KS
patients in the MN-clusters, 16 (70%) were shown to be first-
degree relatives within the cluster, and 14 of these belonged to
clusters with CI-low$10 (Fig. 1). The genealogy revealed a family
of five affected individuals with KS in two generations (Fig. 2).
Two family members belonged to the same MN-cluster, and
a third sibling and an affected cousin were connected to the family
through genealogy work. We were able to confirm the mother’s
KS diagnosis (she had died in 1962) from the radiotherapy records
after it was verbally reported by her daughter.
The geographical distribution of KS incidence according to
municipality of birth of the 537 KS patients in FCR showed
a strikingly uneven pattern (Fig. 3). Patients accumulate almost
entirely to the rural areas of Western Finland. Another aggrega-
Figure 1. Familial Kaposi sarcoma (KS) cases in Finland; each
flag marks a confirmed familial KS patient belonging to
a cluster of municipality of birth and family name at birth
(MN-cluster). Red and blue colors represent the lower confidence limit
(CI-low) of MN-clusters. The borders of Finland are based on those
before year 1940.
doi:10.1371/journal.pone.0055209.g001
Figure 2. Expansion of a key pedigree; a family of five patients
with Kaposi sarcoma (KS) from Eastern Finland. The age at
diagnosis of KS is shown for each affected individual.
doi:10.1371/journal.pone.0055209.g002
Registry-Based Analysis of Cancer Clustering
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tion of KS patients is seen in Northeastern Finland, while Eastern
Finland displays much less KS cases than expected by chance.
Interestingly, the family of five patients (Fig. 2) originates from
Eastern Finland, whereas most of the other ascertained familial
cases originate from Western Finland (Fig. 1).
Human herpesvirus 8, also known as Kaposi sarcoma-associated
herpesvirus, is a well-known etiologic factor for KS. To study
whether the uneven clustering of KS cases resulted from the
uneven distribution of HHV8 infections in Finland, we studied the
seroprevalence of HHV8 in 400 individuals from Eastern and
Western Finland. Four out of 400 individuals (1%) were HHV8
positive. Two of them originated from Eastern Finland and two
from Western Finland, suggesting similar seroprevalence of HHV8
in Eastern and Western Finland. However, the numbers are far
too small for a proper conclusion on possible geographical
variation of HHV8 infection in Finland.
Discussion
Here we have used an approach to systematically analyze
familial aggregation of all tumor types in nation-wide registry-
based data. Unlike most traditional epidemiological tools, our
approach was able to derive evidence for familial occurrence of
both common and rare tumor types. Tumor types showing the
greatest potential for familial occurrence were those that are
mainly seen in rare cancer predisposition syndrome patients -
a proof of concept that the method works well in estimating
familial occurrence. Unexpectedly, one of the top scoring tumor
types was Kaposi sarcoma with strong familial aggregation and
uneven geographical distribution. We were able to identify seven
families with two first-degree relatives with KS, and a family with
five KS cases, which to our knowledge is the third largest reported
KS family worldwide [16,17].
The described clustering method is designed to identify cancer
cases with similar phenotype and common family name at birth,
thus the method is able to detect also potential relatives outside the
nuclear family. The method is also applicable to other registered
diseases than cancer. Primary requirement is to obtain information
about family names and municipalities of patients, while
population-scaled data is needed for calculation of statistical
significance. Populations with enough diversity in family names
are suitable for similar clustering efforts and allow the formation of
statistically significant clusters. Due to the fact that family name in
Finland is usually inherited from father, the birth name-
municipality based clustering method is restricted to finding
family links only from the paternal side.
In this study, we were able to cover significantly more cases and
more detailed tumor types compared to previous familial
clustering efforts, such as those conducted in Icelandic [18] or
Utah population databases [19,20]. One limitation of our effort is
the lack of such extensive genealogy data for the studied
individuals as in the studies in Iceland or Utah. However, the
diversity of family names in Finland (,100,000) and relatively little
migration before World War II – the time period when most of the
cancer cases in FCR were born – warrants our search for familial
occurrence with MN-clustering. In our example case of KS, we
were able to ensure familial relations through NPR and PRs for
70% of the cases in MN-clusters, and 88% of these clusters were of
high statistical significance with the lower confidence limit greater
than ten. Thus, calculating the statistical significance of clustering,
and choosing clusters with the high O/E and CI-low values
obviously increase the probability of identifying true relatives.
We concentrated on the most significant MN-clusters to
estimate the familial occurrence of the tumor types using cluster
score. Top two tumor types indicated known rare cancer
syndromes, namely Von Hippel-Lindau syndrome and Multiple
Endocrine Neoplasia type 2, suggesting that our approach is
feasible in identifying families with high-penetrance cancer
predisposition. One of the most interesting phenotypes with a high
cluster score was KS, which showed high tendency to cluster with
a frequency exceeding, for example, that seen in Wilm’s tumor.
Another phenotype among the top tumor types without known
genetic etiology was neuroendocrine carcinoma of small intestine,
for which high familial risk has been described earlier [3,21].
Twin studies and systematic registry-based studies of all cancers
have been restricted to demonstrate the hereditary effect
concerning the most common cancer sites. In our study, the
strongest evidence for familial occurrence among the most
common tumor types was shown for papillary thyroid adenocar-
cinoma, chronic lymphatic leukemia, and squamous cell carcino-
ma of the lip, each with over 7000 registered patients in FCR. The
very same cancer sites, although without detailed morphology
definitions, showed significant relatedness also in distant familial
relationships (no closer than first cousins) in Utah [20].
KS is a prevalent tumor type especially among HIV-infected
patients and in sub-Saharan Africa [22]. HHV8 is a well-
established etiologic factor for KS, and it is well acknowledged that
Figure 3. The observed/expected (O/E) ratios of Kaposi
sarcoma (KS) incidence according to municipality of birth.
Persons born in rural Western Finland have much higher incidence of KS
than persons born in Eastern Finland. Twenty-one largest cities are
indicated by circles. The white lining is superimposed on the colors of
the sparsely populated areas in Northern Finland (less than 1 inhabitant
per km2). The borders of Finland are based on those before year 1940.
doi:10.1371/journal.pone.0055209.g003
Registry-Based Analysis of Cancer Clustering
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patients suffering from immunosuppressive conditions have higher
risk for KS [23,24]. A few reports exist on familial occurrence of
KS [16,17,25–28]. Accumulating evidence suggests genetic
background as a predisposing factor to KS. A number of studies
have associated certain human leukocyte alleles, and genetic
variants in other host immunity related genes, with predisposition
to KS [29–35]. However, no conclusive mutations predisposing to
familial KS have thus far been reported. KS is a vascular tumor
with an average incidence of 0.1–0.2 per 100,000 person-years in
Finland in 1963–2010, adjusted for age to the World Standard
Population. The incidence of KS according to municipality of
birth varied strongly in Finland. Most KS patients were born near
the west coast, leaving Eastern Finland with significantly fewer KS
cases (Fig. 3). It is well reported, in a number of seroepidemio-
logical studies, that HHV8 infection rates differ geographically
[36]. Whether the west-east difference in the incidence is due to
prevalence of the virus or local founder effect remains to be
studied more carefully. Our preliminary serological analyses
showed that the HHV8 infection is rare in Finland, and does
not seem to be differentially distributed. HHV8 seroprevalence has
not been studied in Finland earlier, whereas Finland’s neighboring
countries, Sweden in the west and Russia in the east, show
seroprevalences of 10–20% and ,10%, respectively [22]. The risk
of HHV8 infection is higher among family members of classic KS
patients, and person-to-person transmission has been confirmed by
the observation that in almost all cases the same viral genotype was
shared within the family [37,38]. While intrafamilial transmission
of HHV8 probably plays a role in the familial occurrence of KS in
our data, it cannot explain in itself the number of KS patients as
high as five within a single family without additional susceptibility
to develop tumors.
It is likely that some high-penetrance tumor predisposing genes
– particularly those of recessive inheritance and those that do not
display easily recognizable syndromic features – remain un-
identified. Poorly characterized combinations of multiple germline
variants with moderate penetrance are likely to explain some
proportion of the hereditary cancer burden. While such genetic
susceptibility factors have previously been difficult to study, the
molecular tools available for hereditary cancer gene identification
have improved dramatically in recent years. Next-generation
sequencing has highlighted the utility of very small numbers of
carefully chosen affected individuals in genetic analyses [35,39,40].
Our approach is useful in deriving the most valuable specimens
from the whole population for analyses of new cancer susceptibility
conditions, including archival tissue blocks that can be utilized for
generation of high-throughput DNA data for predisposition
variant detection.
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